NeOnc Technologies Reports $8.8 Million Net Loss, Sees Decrease in Operating Expenses

NeOnc Technologies Holdings, Inc. reported a net loss of $8.8 million for the three months ended March 31, 2026, a significant reduction from the $32.3 million loss recorded in the same period of the previous year. The company did not generate any revenue during this quarter, compared to $39,990 in revenue from a humanitarian program in the prior year. Total operating expenses decreased to $7.1 million from $31.9 million, primarily due to a substantial reduction in stock-based compensation and advisory fees, which fell from $17.4 million and $11.7 million, respectively, to $2.7 million and $1.4 million.

The company's financial position showed improvement, with total assets increasing to $3.3 million as of March 31, 2026, up from $2.8 million at the end of 2025. Cash and cash equivalents rose to $138,601, compared to $58,729 at the end of the previous fiscal year. NeOnc's accumulated deficit also increased to $121.6 million, reflecting ongoing operational losses. The company’s total liabilities decreased to $16.6 million from $20.3 million, largely due to a reduction in accrued expenses and related party obligations.

Strategically, NeOnc has been active in expanding its operations and product development. The company is advancing its lead product candidates, NEO100 and NEO212, which are in various stages of clinical trials for treating glioblastoma. Additionally, NeOnc established a wholly-owned subsidiary, NuroMENA Holdings Ltd., to oversee clinical operations in the Middle East and North Africa, although this subsidiary was inactive as of the reporting date. The company also entered into a series of Securities Purchase Agreements in January 2026, which are expected to provide up to $16 million in gross proceeds.

Operationally, NeOnc's research and development expenses increased to $1.3 million, driven by costs associated with clinical trials and patient recruitment efforts. The company has also been focusing on enhancing its internal controls and financial reporting processes, following the identification of material weaknesses in its internal control over financial reporting. Management is taking steps to address these issues, including hiring a Chief Accounting Officer and engaging consultants to improve user access management and risk assessment processes.

Looking ahead, NeOnc faces substantial doubt regarding its ability to continue as a going concern, as it has not yet generated significant revenue and relies heavily on external financing. The company is actively pursuing additional funding sources to support its operations and product development initiatives. NeOnc's future capital requirements will depend on various factors, including the costs of clinical trials, regulatory approvals, and the potential commercialization of its product candidates.